Eagle Health Investments LP Increases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Eagle Health Investments LP grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 11.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 627,600 shares of the biopharmaceutical company’s stock after acquiring an additional 65,900 shares during the period. Ultragenyx Pharmaceutical accounts for approximately 6.5% of Eagle Health Investments LP’s investment portfolio, making the stock its 7th biggest holding. Eagle Health Investments LP’s holdings in Ultragenyx Pharmaceutical were worth $26,403,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Smartleaf Asset Management LLC raised its holdings in Ultragenyx Pharmaceutical by 259.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 493 shares in the last quarter. True Wealth Design LLC bought a new position in Ultragenyx Pharmaceutical in the third quarter worth about $43,000. Human Investing LLC purchased a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth about $42,000. Wilmington Savings Fund Society FSB bought a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $83,000. Finally, Nomura Asset Management Co. Ltd. purchased a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $93,000. 97.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total transaction of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares in the company, valued at approximately $2,358,014.08. This represents a 5.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 11,727 shares of the firm’s stock in a transaction dated Monday, December 30th. The stock was sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the transaction, the chief executive officer now directly owns 2,183,985 shares in the company, valued at $92,229,686.55. The trade was a 0.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 136,370 shares of company stock worth $5,751,499. 5.80% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $37.98 on Thursday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $36.71 and a 1 year high of $60.37. The stock’s fifty day moving average price is $41.72 and its 200-day moving average price is $47.08. The company has a market cap of $3.51 billion, a P/E ratio of -5.99 and a beta of 0.67.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on RARE. Wedbush reaffirmed a “neutral” rating and issued a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. Piper Sandler lowered their price target on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research report on Monday, March 17th. Canaccord Genuity Group raised their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $91.71.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.